HUP0303143A2 - A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása - Google Patents

A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása

Info

Publication number
HUP0303143A2
HUP0303143A2 HU0303143A HUP0303143A HUP0303143A2 HU P0303143 A2 HUP0303143 A2 HU P0303143A2 HU 0303143 A HU0303143 A HU 0303143A HU P0303143 A HUP0303143 A HU P0303143A HU P0303143 A2 HUP0303143 A2 HU P0303143A2
Authority
HU
Hungary
Prior art keywords
factor
polypeptides
factor vii
combined use
polypeptide
Prior art date
Application number
HU0303143A
Other languages
English (en)
Inventor
Ulla Hedner
Jens Bjerre Knudsen
Rasmus Rojkjer
Original Assignee
Novo Nordisk Health Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care Ag filed Critical Novo Nordisk Health Care Ag
Publication of HUP0303143A2 publication Critical patent/HUP0303143A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány egy gyógyszerkészítményre vonatkozik, amely egy VII-esfaktort vagy a VII-es faktorral rokon polipeptid készítményt és egyIX-es faktort vagy a IX-es faktorral rokon polipeptid készítményttartalmaz. A találmány vonatkozik továbbá a VII-es faktor vagy a VII-es faktorral rokon polipeptid és a IX-es faktor vagy a IX-es faktorralrokon polipeptid alkalmazására is egy gyógyszerkészítményelőállítására, valamint annak alkalmazási eljárásaira is egy alanybana vérzések megelőzésére és kezelésére. Ó
HU0303143A 2001-02-05 2002-02-05 A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása HUP0303143A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100186 2001-02-05
PCT/DK2002/000080 WO2002062376A1 (en) 2001-02-05 2002-02-05 Combined use of factor vii polypeptides and factor ix polypeptides

Publications (1)

Publication Number Publication Date
HUP0303143A2 true HUP0303143A2 (hu) 2003-12-29

Family

ID=8160159

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0303130A HUP0303130A2 (hu) 2001-02-05 2002-02-05 A VII-es faktor és a VIII-as faktor polipeptidek kombinált alkalmazása és ezeket tartalmazó gyógyszerkészítmények
HU0303143A HUP0303143A2 (hu) 2001-02-05 2002-02-05 A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0303130A HUP0303130A2 (hu) 2001-02-05 2002-02-05 A VII-es faktor és a VIII-as faktor polipeptidek kombinált alkalmazása és ezeket tartalmazó gyógyszerkészítmények

Country Status (16)

Country Link
US (5) US20030199444A1 (hu)
EP (2) EP1359935A1 (hu)
JP (2) JP2004517949A (hu)
KR (2) KR20030088430A (hu)
CN (2) CN1499981A (hu)
AT (1) ATE386538T1 (hu)
AU (1) AU2002229510A1 (hu)
BR (2) BR0207007A (hu)
CA (2) CA2437015A1 (hu)
DE (1) DE60225118T2 (hu)
ES (1) ES2301624T3 (hu)
HU (2) HUP0303130A2 (hu)
IL (2) IL156843A0 (hu)
PL (2) PL365290A1 (hu)
RU (2) RU2311923C2 (hu)
WO (2) WO2002062376A1 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
ATE300953T1 (de) * 2000-05-10 2005-08-15 Novo Nordisk Healthcare Ag Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
BR0113854A (pt) 2000-09-13 2004-07-06 Novo Nordisk As Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ES2376694T3 (es) * 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
RU2347574C2 (ru) * 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
RU2006144397A (ru) * 2004-06-21 2008-07-27 Ново Нордиск Хелс Кеа Аг (Ch) ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ
WO2006089966A2 (en) * 2005-02-28 2006-08-31 Novo Nordisk Health Care Ag Fxiii variants with improved properties
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2008009634A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
US20100143326A1 (en) * 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
EP1988101A1 (en) * 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
CN102026653B (zh) * 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
CN101918025A (zh) 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP4382170A2 (en) * 2009-12-06 2024-06-12 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
JP2013517782A (ja) * 2010-01-28 2013-05-20 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 因子ｖｉｉ融合ポリペプチド
AU2011313505B2 (en) 2010-10-06 2015-09-17 Medimmune Limited Factor II and fibrinogen for treatment of haemostatic disorders
AU2011316575B2 (en) * 2010-10-12 2015-10-29 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia B
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US20210355231A1 (en) * 2018-09-06 2021-11-18 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
CN114728044A (zh) * 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550011C2 (de) * 1975-11-07 1982-11-25 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines antihämophilen Mittels
DE2759053A1 (de) * 1977-12-30 1979-07-12 Uhlin Verfahren zum herstellen von genprodukten von plasmid-dns
WO1981002105A1 (en) * 1980-01-28 1981-08-06 Baxter Travenol Lab Therapeutic compositions & methods for manufacture and use
US4381119A (en) * 1980-12-17 1983-04-26 Burroughs Corporation Multipart continuous form
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
ATE300953T1 (de) * 2000-05-10 2005-08-15 Novo Nordisk Healthcare Ag Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030118580A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
EP1446150A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors

Also Published As

Publication number Publication date
US20030199444A1 (en) 2003-10-23
CN1499981A (zh) 2004-05-26
US20060211621A1 (en) 2006-09-21
EP1359936B1 (en) 2008-02-20
KR20030078901A (ko) 2003-10-08
ATE386538T1 (de) 2008-03-15
IL156842A0 (en) 2004-02-08
HUP0303130A2 (hu) 2004-01-28
RU2292909C2 (ru) 2007-02-10
KR20030088430A (ko) 2003-11-19
US20080076702A1 (en) 2008-03-27
EP1359935A1 (en) 2003-11-12
WO2002062376A1 (en) 2002-08-15
AU2002229510A1 (en) 2002-08-19
ES2301624T3 (es) 2008-07-01
WO2002062377A2 (en) 2002-08-15
US20080075711A1 (en) 2008-03-27
CA2437015A1 (en) 2002-08-15
JP2004517950A (ja) 2004-06-17
PL365290A1 (en) 2004-12-27
BR0207007A (pt) 2004-02-17
JP2004517949A (ja) 2004-06-17
PL365293A1 (en) 2004-12-27
IL156843A0 (en) 2004-02-08
DE60225118D1 (de) 2008-04-03
RU2311923C2 (ru) 2007-12-10
US20060276398A1 (en) 2006-12-07
DE60225118T2 (de) 2009-03-05
CN1592632A (zh) 2005-03-09
RU2003126911A (ru) 2005-02-27
CA2436807A1 (en) 2002-08-15
WO2002062377A3 (en) 2003-03-27
EP1359936A2 (en) 2003-11-12
BR0207006A (pt) 2004-02-17
RU2003127018A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
HUP0303143A2 (hu) A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása
HUP0303996A2 (hu) Vakcinakészítmények
HUP0401124A2 (hu) VII koagulációs faktor származékok
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
HUP0400149A2 (hu) Új fertőtlenítőszerek
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
HK1084404A1 (en) Muteins of tear lipocalin
HUP0301281A2 (hu) Új gyógyászati készítmény
HUP0003386A2 (hu) CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
HUP0400782A2 (hu) Antikolinergikumokon és PDE-IV inhibitorokon alapuló új gyógyszerkészítmények
SE0301653D0 (sv) Novel compounds
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
TNSN04206A1 (en) Novel perindopril salt and pharmaceutical compositions containing same
BR9809306A (pt) Inibidores de protease
HUP0300701A2 (hu) Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0400976A2 (hu) VII-es faktor polipeptideket és XI-es faktor polipeptideket tartalmazó gyógyszerészeti összetételek
HUP0302441A2 (hu) Antibiotikus hatású gyógyászati készítmények
HUP0303154A2 (hu) Az oxkarbazepin új kristályformái, és az előállításukra szolgáló eljárások
HUP0304050A2 (hu) Módosított FVII az ARDS kezelésre
HUP0401633A2 (hu) Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees